⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249791 | 0.85 | ITGB1 (0.30) | — | |
| SCHEMBL22188609 | 0.82 | — | — | |
| SCHEMBL7621501 | 0.71 | — | — | |
| SCHEMBL23437879 | 0.71 | — | — | |
| SCHEMBL24090046 | 0.71 | — | — | |
| SCHEMBL13958289 | 0.70 | HSD11B1 (0.32) | — | |
| SCHEMBL7158743 | 0.67 | MTNR1A (0.31) | — | |
| SCHEMBL22570557 | 0.67 | MTNR1A (0.31) | — | |
| SCHEMBL2484399 | 0.66 | DAO (0.32) | — | |
| SCHEMBL7165801 | 0.66 | CCR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-10800749-B2 | Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190337911-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-11-07 | — | — | US | disclosed |
| US-20150361060-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361060-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361060-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-17 | — | — | US | disclosed |
| WO-2013061973-A1 | HETEROARYL SULFONAMIDE COMPOUND OR SALT THEREOF | 石原産業株式会社 (JP) | 2013-05-02 | — | — | WO | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-6071906-A | INHIBITS OR MODULATES THE INDUCIBLE ISOFORM OF NITRIC OXIDE SYNTHASE OVER THE THE CONSTITUTIVE ISOFORMS; ANTIARTHRITIC, -DIABETIC, ISCHEMIC, THROMBOSIS AGENTS; CARDIOVASCULAR DISORDERS; TOXIC SHOCK SYNDROME; AUTOIMMUNE DISEASES | G. D. SEARLE & CO. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6046211-A | TREATMENT OF ARTHRITIS OR INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA (ALLODYNIA), CEREBRAL ISCHEMIA AND OTHER CNS DISORDERS | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0968198-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE | Elan Pharmaceuticals, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0724570-B1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0897912-A1 | Amidino derivatives useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |